

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001779990  
Filer CCC XXXXXXXXX  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144: Issuer Information

Name of Issuer Apogee Therapeutics, Inc.  
SEC File Number 001-41740  
Address of Issuer 221 CRESCENT ST.  
BUILDING 17, SUITE 102B  
WALTHAM  
MASSACHUSETTS  
02453  
Phone 650-394-5230  
Name of Person for Whose Account the Securities are To Be Sold HENDERSON MICHAEL THOMAS

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer  
Relationship to Issuer Director

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	RBC WEALTH MANAGEMENT 250 NICOLLET MALL, SUITE 1700 MINNEAPOLIS MN 55401	40000	2249176.00	58546027	10/02/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	05/22/2022	INCENTIVE UNIT CONVERSION	ISSUER	<input type="checkbox"/>		40000	05/22/2022	N/A

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MICHAEL HENDERSON 4147 26TH STREET SAN FRANCISCO CA 94131	APOGEE THERAPEUTICS INCORPORATED	07/05/2024	15000	558915.00
MICHAEL HENDERSON 4147 26TH STREET SAN FRANCISCO CA 94131	APOGEE THERAPEUTICS INCORPORATED	08/07/2024	40000	1624784.00
MICHAEL HENDERSON 4147 26TH STREET SAN FRANCISCO CA 94131	APOGEE THERAPEUTICS INCORPORATED	09/04/2024	40000	1904848.00

## 144: Remarks and Signature

Remarks SOLD PURSUANT TO A RULE 10B5-1 PLAN  
ESTABLISHED 09/25/2023

Date of Notice 10/02/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 09/25/2023

### ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature POA / JEFFREY EISCHENS

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**